Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - March 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Lacosamide (Vimpat®) has been rejected for use as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2018' on Email Share 'SMC Update - March 2018' on Delicious Share 'SMC Update - March 2018' on Digg Share 'SMC Update - March 2018' on Facebook Share 'SMC Update - March 2018' on reddit Share 'SMC Update - March 2018' on StumbleUpon Share 'SMC Update - March 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - March 2018”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer